September 7, 2022 7:37am

And that ain’t all; arguably the cell and gene therapy sector is due for a bounce; but the weakness is expressive.

Indications: 2 Positive Indications and 1 Pump/Promotes

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

More frequently right than consequentially wrong; there is VALUE out there. What I provide is an intelligence daily.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.15% or (+48 points), S&P futures are UP +0.18% (+7 points) and NASDAQ futures are UP +0.19% (+22 points) early in the pre-open – so far,


Stock futures were inching yet flat Wednesday,

European markets retreat as recession fears grow,

Asia-Pacific markets fall.



Indexes added to their three-week slide in regular trading while major indexes fell further from their 50-day moving averages. The Dow fell about 173 points or 0.5%, and the S&P 500 slid 0.4% while the Nasdaq dropped 0.7% to notch its first seven-day losing streak since 2016.

Investors are split on how to approach the market entering the first post-Labor Day week in September, a notoriously cruel month for stocks. <CNBC>

Economic Data Docket: Mortgage demand drops further as interest rates shoot back to June high. The average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances increased to 5.94% last week from 5.80% the previous week, according to the Mortgage Bankers Association.


RegMed Investors’ (RMi) Wednesday’s closing bell: sector takes it in the shins as value propositions get lost in sentiment’s retreat as Fed worries persist while any cell and gene therapy sector financing options dissolve.” …


Ebb and flow –

Q3/22 – September – 1 holiday, 1 positive and 2 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes

Q2/22 –

·         June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive Indications:

Caribou Biosciences (CRBU) closed up +$0.44 to $10.29 following Monday’s holiday and Friday -$0.68 after Thursday’s -$0.65 with a positive +$0.46 or +4.47% pre-open indication.

uniQure NV (QURE) closed down -$1.116 to $19.50 after Monday’s holiday following Friday’s $20.66 and Thursday’s $20.67 with a positive +$0.55 or +2.82% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat with 34 shares traded on Tuesday after Monday’s holiday following Friday’s $0.00 Thursday’s $0.00 and last Wednesday’s $0.00 <3-month average = 1,617>,

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities?


The BOTTOM LINE: I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!

August is over with 1 neutral, 11 positive and 11 negative closes while last week which ended the month.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash? Start by looking at cell and gene therapy companies trading below cash!” 

How many companies are LOSING the investment high ground? TOO MANY …!!!

Investors need to come to terms of the cell and gene therapy sector’s state of affairs and health as individual company’s actions cast doubts upon sentiment as reflected by August’s final accounting of positive and negative closes.

Companies NEED BETTER outreach to investors which means … NOT to enrich themselves at shareholder’s expense!

CEO salaries, spending the G&A are totally OUT-OF-WHACK; these are companies are in the development stage and will be for years without products in most cases not like the tech companies, who CEOs and management teams think they should be compared to for bi-weekly cash and “beanies”!

When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.

Also, investors can’t afford the outsized valuation price targets by I-Banks research and believe that CEOs are “accomplices” to over-estimating expectation and guidance in regard to valuation

The only thing investors are able to hang to at that point is HOPE – which is not a technical or fundamental indicator.  Keep your eyes on historical pricings that, haven’t responded to I-Bank research price targets.

As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”

That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.